Genmab (Otc) (GMAB) has released an update.
Genmab A/S, the Danish biotechnology firm, has been actively purchasing its shares back and has acquired a total of 194,403 shares amounting to DKK 400.8 million as part of its DKK 3.5 billion buy-back program set to conclude by December 16, 2024. These recent transactions have increased the company’s treasury shares to 1.60% of its total share capital. Genmab, renowned for its novel antibody therapeutics, is executing this buy-back under European market regulations and continues to forge partnerships aimed at transforming patient lives with innovative medicines.
For further insights into GMAB stock, check out TipRanks’ Stock Analysis page.
